APA (7th ed.) Citation

Salles, G., Schuster, S. J., de Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., . . . Gopal, A. K. (2017). Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica (Roma), 102(4), e156-e159. https://doi.org/10.3324/haematol.2016.151738

Chicago Style (17th ed.) Citation

Salles, Gilles, et al. "Efficacy and Safety of Idelalisib in Patients with Relapsed, Rituximab- and Alkylating Agent-refractory Follicular Lymphoma: A Subgroup Analysis of a Phase 2 Study." Haematologica (Roma) 102, no. 4 (2017): e156-e159. https://doi.org/10.3324/haematol.2016.151738.

MLA (9th ed.) Citation

Salles, Gilles, et al. "Efficacy and Safety of Idelalisib in Patients with Relapsed, Rituximab- and Alkylating Agent-refractory Follicular Lymphoma: A Subgroup Analysis of a Phase 2 Study." Haematologica (Roma), vol. 102, no. 4, 2017, pp. e156-e159, https://doi.org/10.3324/haematol.2016.151738.